Tumors contain a sub-population of self-renewing and expanding cells known as cancer stem cells (CSCs). Putative CSCs were isolated from human melanoma cells of a different aggressiveness, Hs294T and A375 cell lines, grown under hypoxia using "sphere-forming assay", CD133 surface expression and migration ability. We found that a cell sub-population enriched for P1 sphere-initiating ability and CD133 expression also express larger amount of VEGF-R2. Etoposide does not influence phenotype of this sub-population of melanoma cells, while a combined treatment with Etoposide and Bevacizumab significantly abolished P1 sphere-forming ability, an effect associated with apoptosis of this subset of cells. Hypoxic melanoma cells sorted for VEGF-R2/CD133 positivity also undergo apoptosis when exposed to Etoposide and Bevacizumab. When Etoposide and Bevacizumab-treated hypoxic cells were injected intravenously into immunodeficient mice revealed a reduced capacity to induce lung colonies, which also appear with a longer latency period. Hence, our study indicates that a combined exposure to Etoposide and Bevacizumab targets melanoma cells endowed with stem-like properties and might be considered a novel approach to treat cancer-initiating cells
Etoposide-Bevacizumab a new strategy against human melanoma cells expressing stem-like traits / Calvani, M; Bianchini, F; Taddei, Ml; Becatti, M; Giannoni, E; Chiarugi, P; Calorini, L1.. - In: ONCOTARGET. - ISSN 1949-2553. - ELETTRONICO. - 7(33):(2016), pp. 51138-51149. [10.18632/oncotarget.9939]
Etoposide-Bevacizumab a new strategy against human melanoma cells expressing stem-like traits
CALVANI, MAURA;BIANCHINI, FRANCESCA;TADDEI, MARIA LETIZIA;BECATTI, MATTEO;GIANNONI, ELISA;CHIARUGI, PAOLA;CALORINI, LIDO
2016
Abstract
Tumors contain a sub-population of self-renewing and expanding cells known as cancer stem cells (CSCs). Putative CSCs were isolated from human melanoma cells of a different aggressiveness, Hs294T and A375 cell lines, grown under hypoxia using "sphere-forming assay", CD133 surface expression and migration ability. We found that a cell sub-population enriched for P1 sphere-initiating ability and CD133 expression also express larger amount of VEGF-R2. Etoposide does not influence phenotype of this sub-population of melanoma cells, while a combined treatment with Etoposide and Bevacizumab significantly abolished P1 sphere-forming ability, an effect associated with apoptosis of this subset of cells. Hypoxic melanoma cells sorted for VEGF-R2/CD133 positivity also undergo apoptosis when exposed to Etoposide and Bevacizumab. When Etoposide and Bevacizumab-treated hypoxic cells were injected intravenously into immunodeficient mice revealed a reduced capacity to induce lung colonies, which also appear with a longer latency period. Hence, our study indicates that a combined exposure to Etoposide and Bevacizumab targets melanoma cells endowed with stem-like properties and might be considered a novel approach to treat cancer-initiating cellsFile | Dimensione | Formato | |
---|---|---|---|
69 Calvani et al Etoposide Bevacizumab.pdf
accesso aperto
Descrizione: Articolo principale
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
6.38 MB
Formato
Adobe PDF
|
6.38 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.